Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...
A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated ...
All participants had adverse events, but most were moderate in severity ...
A new study in the journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are encapsulated into recombinant adeno-associated virus (rAAV) capsids as ...
Based on Ajinomoto Group’s collaborative development with Forge Biologics, now available worldwide Incheon, Korea — December 2025 — Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group ...
The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through ...
Nine-year follow-up of gene therapy in haemophilia B confirms long-term safety and reduced bleeding, though full capsid ...